Nampt (Visfatin/PBEF) (human) (IntraCellular) ELISA Kit
Product Code:
AG-45A-0008Y
AG-45A-0008Y
Regulatory Status:
RUO
RUO
Target Species:
Human
Human
Application:
Enzyme-Linked Immunosorbent Assay (ELISA)
Enzyme-Linked Immunosorbent Assay (ELISA)
Shipping:
BLUE ICE
BLUE ICE
Storage:
Short term: +4°C. Long term: +4°C
Short term: +4°C. Long term: +4°C
No additional charges, what you see is what you pay! *
| Code | Size | Price |
|---|
| AG-45A-0008YEK-KI01 | 96 wells | £600.00 |
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: Switzerland.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
- Further Information
- Documents
- References
- Show All
Further Information
Alternate Names/Synonyms:
Nicotinamide Phosphoribosyltransferase; PBEF1; Pre-B Cell Colony Enhancing Factor 1; Intracellular Nampt
Assay Type:
Sandwich
Detection Type:
Colorimetric
EClass:
32160000
Handling Advice:
After standard reconstitution, prepare aliquots and store at -20°C.Avoid freeze/thaw cycles.Plate and reagents should reach room temperature before use.
Long Description:
ELISA Assay. Detects human Nampt. Weakly cross-reacts (<15%) with mouse Nampt and rat Nampt. Does not cross-react with human adiponectin, human resistin, human RELM-beta or human leptin. Colorimetric assay. Sample Types: Cell Lysate. Range: 0.25 to 16ng/ml. Sensitivity: 30pg/ml. Nicotinamide phosphoribosyltransferase (Nampt; pre-B cell colony-enhancing factor; PBEF; Visfatin) is an 52kDA adipokine secreted by adipose tissue and involved in the biosynthesis of nicotinamide adenine dinucleotide (NAD+). Two forms of Nampt exist, an intracellular form (iNampt) and an extracellular form (eNampt). While the function of iNampt as an essential and rate-limiting NAD+ biosynthetic enzyme is well established, the physiological role of eNampt is still a matter of debate. It has been shown that Nampt expression is increased in different diseases, like diabetes, obesity, fetal growth retardation, sepsis, inflammatory bowel disease, Crohn?s disease and rheumatoid arthritis. Furthermore, Nampt might be a marker of pre-eclampsia and of endothelial health.
NCBI, Uniprot Number:
P43490
Package Type:
Box
Product Description:
Nicotinamide phosphoribosyltransferase (Nampt; pre-B cell colony-enhancing factor; PBEF; Visfatin) is an 52kDA adipokine secreted by adipose tissue and involved in the biosynthesis of nicotinamide adenine dinucleotide (NAD+). Two forms of Nampt exist, an intracellular form (iNampt) and an extracellular form (eNampt). While the function of iNampt as an essential and rate-limiting NAD+ biosynthetic enzyme is well established, the physiological role of eNampt is still a matter of debate. It has been shown that Nampt expression is increased in different diseases, like diabetes, obesity, fetal growth retardation, sepsis, inflammatory bowel disease, Crohn?s disease and rheumatoid arthritis. Furthermore, Nampt might be a marker of pre-eclampsia and of endothelial health.
Range:
0.25 to 16ng/ml
Sample Type:
Cell Lysate
Sensitivity:
30pg/ml
Specificity:
Detects human Nampt. Weakly cross-reacts (<15%) with mouse Nampt and rat Nampt. Does not cross-react with human adiponectin, human resistin, human RELM-beta or human leptin.
Transportation:
Non-hazardous
UNSPSC Category:
ELISA Kits
UNSPSC Number:
41116126
Use & Stability:
12 months after the day of manufacturing. See expiry date on ELISA Kit box.
References
Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes: A. Garten, et al.; BBRC 391, 376 (2010) | Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans: D. Friebe, et al.; Diabetologia 54, 1200 (2011) | Visceral adipose tissue visfatin in nonalcoholic fatty liver disease: R. Gaddipati, et al.; Ann. Hepatol. 9, 266 (2010) | In vivo Suppression of Visfatin by Oral Glucose Uptake: Evidence for a Novel Incretin-Like Effect by Glucagon-Like Peptide-1 (GLP-1): M. Bala, et al.; J. Clin. Endocrinol. Metab. 96, 2493 (2011) | Cisplatin resistance of NSCLC cells involves upregulation of visfatin through activation of its transcription and stabilization of mRNA: Z. Lu, et al.; Chem. Biol. Interact, ahead of print (2021)